| 1 | Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study | 2.3 | 0 | Citations (PDF) |
| 2 | Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial | 5.7 | 22 | Citations (PDF) |
| 3 | Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study | 2.7 | 24 | Citations (PDF) |
| 4 | Phase <scp>II</scp> study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (<scp>GATE</scp> 1) | 4.5 | 25 | Citations (PDF) |
| 5 | No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families | 2.7 | 2 | Citations (PDF) |
| 6 | Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma | 4.0 | 6 | Citations (PDF) |
| 7 | CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM | 4.0 | 7 | Citations (PDF) |
| 8 | The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients | 10.0 | 11 | Citations (PDF) |
| 9 | Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative | 3.3 | 24 | Citations (PDF) |
| 10 | Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) | 2.7 | 14 | Citations (PDF) |
| 11 | Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials | 3.3 | 14 | Citations (PDF) |
| 12 | Modulating PKCα Activity to Target Wnt/β-Catenin Signaling in Colon Cancer | 4.0 | 21 | Citations (PDF) |
| 13 | Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial | 4.8 | 86 | Citations (PDF) |
| 14 | Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy | 1.3 | 3 | Citations (PDF) |
| 15 | Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study | 3.6 | 97 | Citations (PDF) |
| 16 | Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival | 1.9 | 8 | Citations (PDF) |
| 17 | Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab | 14.8 | 23 | Citations (PDF) |
| 18 | Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR | 1.1 | 41 | Citations (PDF) |
| 19 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer | 25.5 | 2,083 | Citations (PDF) |
| 20 | Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results | 1.0 | 13 | Citations (PDF) |
| 21 | Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study | 2.2 | 11 | Citations (PDF) |
| 22 | Reproductive Decision‐Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options | 1.9 | 2 | Citations (PDF) |
| 23 | Neoadjuvant therapy for gastroesophageal adenocarcinoma | 3.1 | 10 | Citations (PDF) |
| 24 | Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | 21.9 | 281 | Citations (PDF) |
| 25 | A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer | 3.4 | 20 | Citations (PDF) |
| 26 | Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA | 25.6 | 553 | Citations (PDF) |
| 27 | A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial | 1.7 | 82 | Citations (PDF) |
| 28 | Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data | 3.3 | 141 | Citations (PDF) |
| 29 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer | 25.5 | 6,041 | Citations (PDF) |
| 30 | Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial | 3.6 | 71 | Citations (PDF) |
| 31 | Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial | 17.1 | 1,654 | Citations (PDF) |
| 32 | Towards a pan-European consensus on the treatment of patients with colorectal liver metastases | 3.3 | 460 | Citations (PDF) |
